Low-dose Decitabine/Cedazuridine Reduces Toxicity While Preserving Efficacy in Low-risk MDS
Low-dose decitabine–cedazuridine shows promising results with the same efficacy as standard dosing but with significantly better safety and tolerability — a potentially new option for patients with low-risk MDS.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
